The nation of Zimbabwe has turned down a substantial US health deal valued at 367 million US dollars (£272m) spanning five years because of the United States' demand for sensitive data.
The decision came to light following a internal memorandum from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "lopsided".
A government representative has since clarified that the US was requesting biological samples for scientific study and profit while refused to guarantee the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable process of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had furnished more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged further talks to secure a agreement acceptable to all parties so the country's vital HIV programme can continue.
Broader Background
This rejection comes after a similar case in Kenya, where a high court halted a related health funding agreement following concerns were raised about the safety of citizens' medical information.
After resuming office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had managed aid for the US government, but Trump stated its spending was "wasteful" and his administration was seeking direct bilateral agreements to boost openness and responsibility.
Based on statements, 16 nations in Africa have so far signed similar health pacts, representing more than $18.3bn in new funding.
Specifics of the Rejected Deal
The funds for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration might have yielded extraordinary advantages for Zimbabwean communities, especially the 1.2 million currently receiving HIV treatment through American-funded initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to provide its genetic material and health information indefinitely, without any corresponding promise of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"In essence, our country would provide the basic resources for medical research without any assurance that the resulting innovations would be accessible to our population should a future disease outbreak arise."
National Interest and Global Health
Mangwana further pointed out that the American exit from the global health body and its pursuit of one-on-one health agreements were upending frameworks previously established via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system designed to deal with future global health emergencies.
"This system is intended to ensure that when a nation contributes its information, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," Mangwana stressed.
"We encourage ongoing discussions with our US partners on how subsequent co-operation could be structured in a way that respects the independence and dignity of both nations."
Medical Community Reaction
Medical experts stated it recognised the official position, but suggested that talks must proceed since much of the nation's Aids initiatives depended on foreign aid.
"In cases where specific concerns exist, such as those relating to data governance or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," the group said.
The halted deal underscores the ongoing tensions between accepting crucial international aid and safeguarding national sovereignty in an increasingly interconnected world.